Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
New InsiGHTS
NCT05690386Phase 2Active, not recruiting
- Sponsor
- Ascendis Pharma
- Start
- Feb 2023
- Primary completion
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lonapegsomatropin in Turner syndrome (TS), sponsored by Ascendis Pharma. Started Feb 2023; status: active, not recruiting.
02
Drugs
lonapegsomatropin
03
Conditions
Turner syndrome (TS)
Beyond the preview
Go deeper on NCT05690386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05690386.